The purpose of the current phase II single-arm
clinical trial was to evaluate whether pre-treatment with low-dose
cyclophosphamide improves immunogenicity of a p53-synthetic long peptide
(SLP) vaccine in patients with recurrent ovarian cancer. Ovarian cancer
patients with elevated serum levels of CA-125 after primary treatment
were immunized four times with the p53-SLP vaccine.........The
outcome of this phase II trial warrants new studies on the use of
low-dose cyclophosphamide to potentiate the immunogenicity of the
p53-SLP vaccine, or other anti-tumor vaccines.
